Scientists

A technique developed under the coordination of researchers from the Centre for Genomic Regulation (CRG) and the Institute for Biomedical Research (IRB) in Barcelona has made it possible to track methylation patterns or “barcodes” in blood cells and construct their epigenetic family tree. This has enabled them to trace their evolution and changes with age, which could be useful for disease prevention and for the study or even development of specific therapies against ageing. The results are published in the journal Nature.

A study has identified and tested 22 compounds that inhibit the development of Plasmodium falciparum—one of the parasites that cause malaria—in the mosquitoes that transmit it. The most effective molecule killed 100% of the parasites present within six minutes, even in insecticide-resistant mosquitoes, according to the study published in Nature. These compounds could be used to treat bed nets.

By 2030, there will be more than 1 billion adolescents (aged 10 to 24) living in countries facing preventable and treatable health issues. This figure represents half of the world’s adolescent population, according to a new analysis by the Lancet Commission on adolescent health and well-being. Among these health issues, the study highlights HIV/AIDS, early pregnancies, risky sexual behavior, depression, poor nutrition, and injuries.

A US study analysing data from nearly 700,000 people concluded that those with a history of herpes simplex virus (HSV-1) infections were at greater risk of developing Alzheimer's disease. The study, published in BMJ Open, also showed that patients with this virus who used anti-herpes treatments were less likely to develop the disease.

The Member States of the World Health Organisation (WHO), meeting on Monday in Committee A of the World Health Assembly, approved a resolution calling for the adoption of a historic global pact to make the world safer from future pandemics. On Tuesday, the Assembly, in plenary session, adopted by consensus the world's first agreement on pandemics.

In online debates, Large Language Models (LLMs, i.e. Artificial Intelligence systems such as ChatGPT) are more persuasive than humans when they can personalise their arguments based on their opponents’ characteristics, says a study published in Nature Human Behaviour which analysed GPT-4. The authors urge researchers and online platforms to ‘seriously consider the threat posed by LLMs fuelling division, spreading malicious propaganda and developing adequate countermeasures'.

New gene editing technologies, such as gene drive tools, open the door to deliberately extinguishing species. An analysis article published in Science examines the ethical implications of this possibility based on three specific examples: the eradication of rats, the cattle barren worm, and the Anopheles gambiae mosquito, which transmits malaria. The analysis attempts to answer the question: ‘When and under what circumstances could the intentional eradication of a species be justified?".

A team from the Children's Hospital of Philadelphia and Penn Medicine (United States) has successfully treated a baby diagnosed with a rare genetic disorder using personalised CRISPR gene editing therapy. The baby, known only by the initials KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in hospital on a very restrictive diet, KJ received the first dose of his tailored therapy in February 2025, between six and seven months of age. The treatment, which is being used for the first time for this type of disorder, was administered safely, and the baby is now growing well and improving. The case is detailed in a study published by The New England Journal of Medicine (NEJM).

Research involving more than 200 patients with depression, whose symptoms had not improved after NHS talk therapy shows that those who took part in eight group sessions of mindfulness-based cognitive therapy saw their depressive symptoms reduced, compared with those who received treatment as usual. The study is published in The Lancet Psychiatry.

Narcolepsy type 1 is a sleep disorder characterised by excessive daytime sleepiness and cataplexy - sudden loss of muscle tone. Existing treatments are based on palliation of symptoms, with moderate success. Now, an international phase 2 clinical trial, involving CEU San Pablo University and other Spanish centres, published in the journal NEJM, shows the results of a new drug targeting the cause of the disorder. Overall, the benefits appear superior and no serious adverse effects were observed. According to the authors, ‘the results are promising’ and represent ‘a very significant impact on the quality of life of these patients’.